AAAAAA
Results:
1-21
|
Results: 21
Authors:
Johnston, SRD
Citation: Srd. Johnston, Systemic treatment of metastatic breast cancer, HOSP MED, 62(5), 2001, pp. 289-295
Authors:
Johnston, SRD
Kaye, S
Citation: Srd. Johnston et S. Kaye, Caelyx: treatment for relapsing ovarian cancer, HOSP MED, 62(10), 2001, pp. 611-616
Authors:
Johnston, SRD
Kelland, LR
Citation: Srd. Johnston et Lr. Kelland, Farnesyl transferase inhibitors - a novel therapy for breast cancer, ENDOCR-R CA, 8(3), 2001, pp. 227-235
Authors:
Kelland, LR
Smith, V
Valenti, M
Patterson, L
Clarke, PA
Detre, S
End, D
Howes, AJ
Dowsett, M
Workman, P
Johnston, SRD
Citation: Lr. Kelland et al., Preclinical antitumor activity and pharmacodynamic studies with the farnesylprotein transferase inhibitor R115777 in human breast cancer, CLIN CANC R, 7(11), 2001, pp. 3544-3550
Authors:
Saunders, Y
Stebbing, J
Broadley, K
Johnston, SRD
Citation: Y. Saunders et al., Recurrent locally advanced breast cancer: The treatment of chest wall disease with further chemotherapy, CL ONCOL-UK, 13(3), 2001, pp. 195-199
Authors:
Johnston, SRD
Smith, IE
Dowsett, M
Citation: Srd. Johnston et al., Place of aromatase inhibitors in the endocrine therapy of breast cancer, AROMATASE INHIBITION AND BREAST CANCER, 2001, pp. 29-49
Authors:
Johnston, SRD
Citation: Srd. Johnston, Irreversible aromatase inactivation: treatment for breast cancer, HOSP MED, 61(9), 2000, pp. 650-655
Authors:
de Boer, RH
Saini, A
Johnston, SRD
O'Brien, MER
Ellis, PA
Verrill, MW
Prendiville, JA
Walsh, G
Ashley, S
Smith, IE
Citation: Rh. De Boer et al., Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study, BREAST, 9(3), 2000, pp. 149-155
Authors:
Gregory, RK
Hill, ME
Moore, J
A'Hern, RP
Johnston, SRD
Blake, P
Shephard, J
Barton, D
Gore, ME
Citation: Rk. Gregory et al., Combining platinum, paclitaxel and anthracycline in patients with advancedgynaecological malignancy, EUR J CANC, 36(4), 2000, pp. 503-507
Authors:
De Boer, RH
Allum, WH
Ebbs, SR
Gui, GPH
Johnston, SRD
Sacks, NPM
Walsh, G
Ashley, S
Smith, IE
Citation: Rh. De Boer et al., Multimodality therapy in inflammatory breast cancer: Is there a place for surgery?, ANN ONCOL, 11(9), 2000, pp. 1147-1153
Authors:
Vaughan, MM
Moore, J
Riches, PG
Johnston, SRD
A'Hern, RP
Hill, ME
Eisen, T
Ayliffe, MJ
Thomas, JM
Gore, ME
Citation: Mm. Vaughan et al., GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): A phase I trial in melanoma, ANN ONCOL, 11(9), 2000, pp. 1183-1189
Authors:
Gregory, RK
Johnston, SRD
Smith, IE
Miles, D
Citation: Rk. Gregory et al., UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer, ONCOLOGY-NY, 14(10), 2000, pp. 47-49
Authors:
Smith, IE
Johnston, SRD
O'Brien, MER
Hickish, TF
de Boer, RH
Norton, A
Cirkel, DT
Barton, CM
Citation: Ie. Smith et al., Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: A phase II study, J CL ONCOL, 18(12), 2000, pp. 2378-2384
Authors:
van der Flier, S
Chan, CMW
Brinkman, A
Smid, M
Johnston, SRD
Dorssers, LCJ
Dowsett, M
Citation: S. Van Der Flier et al., BCAR1/p130CAS expression in untreated and acquired tamoxifen-resistant human breast carcinomas, INT J CANC, 89(5), 2000, pp. 465-468
Authors:
Eisen, T
Boshoff, C
Mak, I
Sapunar, F
Vaughan, MM
Pyle, L
Johnston, SRD
Ahern, R
Smith, IE
Gore, ME
Citation: T. Eisen et al., Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer, BR J CANC, 82(4), 2000, pp. 812-817
Authors:
Dowsett, M
Archer, A
Assersohn, L
Gregory, RK
Ellis, PA
Salter, J
Chang, J
Mainwaring, P
Boeddinghaus, I
Johnston, SRD
Powles, TJ
Smith, IE
Citation: M. Dowsett et al., Clinical studies of apoptosis and proliferation in breast cancer, ENDOCR-R CA, 6(1), 1999, pp. 25-28
Authors:
Dowsett, M
Pfister, C
Johnston, SRD
Miles, DW
Houston, SJ
Verbeek, JA
Gundacker, H
Sioufi, A
Smith, IE
Citation: M. Dowsett et al., Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer, CLIN CANC R, 5(9), 1999, pp. 2338-2343
Authors:
Johnston, SRD
Lu, B
Scott, GK
Kushner, PJ
Smith, IE
Dowsett, M
Benz, CC
Citation: Srd. Johnston et al., Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance, CLIN CANC R, 5(2), 1999, pp. 251-256
Authors:
Palmer, K
Moore, J
Everard, M
Harris, JD
Rodgers, S
Rees, RC
Murray, AK
Mascari, R
Kirkwood, J
Riches, PG
Fisher, C
Thomas, JM
Harries, M
Johnston, SRD
Collins, MKL
Gore, ME
Citation: K. Palmer et al., Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma, HUM GENE TH, 10(8), 1999, pp. 1261-1268
Authors:
Detre, S
Salter, J
Barnes, DM
Riddler, S
Hills, M
Johnston, SRD
Gillett, C
A'Hern, R
Dowsett, M
Citation: S. Detre et al., Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts, INT J CANC, 81(2), 1999, pp. 309-313
Authors:
Johnston, SRD
Boeddinghaus, IM
Riddler, S
Haynes, BP
Hardcastle, IR
Rowlands, M
Grimshaw, R
Jarman, M
Dowsett, M
Citation: Srd. Johnston et al., Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis, CANCER RES, 59(15), 1999, pp. 3646-3651
Risultati:
1-21
|